Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors

M. Murata, M. Harada, S. Kato, S. Takahashi, H. Ogawa, Shinichiro Okamoto, S. Tsuchiya, H. Sakamaki, Y. Akiyama, Y. Kodera

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Adverse events were analyzed in 94 normal donors who underwent PBSC harvest with G-CSF. The median dose of G-CSF was 9.7 μg/kg/day (range, 2.0-16.7), and the duration of administration was 4-6 days. Frequent symptoms were bone pain (71%), general fatigue (33%), headache (28%), insomnia (14%), anorexia (11%), nausea and/or vomiting (11%). One donor (1%) developed grade 3 toxicity bone pain (WHO criteria). WBC counts and ANC increased during G-CSF administration. After leukapheresis, three donors (3%) developed grade 3 toxicity neutropenia. Platelet counts decreased after leukapheresis. Three donors (3%) developed grade 3 thrombocytopenia. The means of both ALP and LDH increased approximately 1.9-fold compared with pretreatment levels. In one pediatric donor (1%), ALP was elevated to the grade 3 toxicity level. From multivariate analysis, the incidence of bone pain increased when GCSF was given at a dose of 8.8 μg/kg/day or more, headaches were frequent in donors younger than 35 years, and the incidence of nausea and/or vomiting was high in female donors. The peak levels of WBC counts and ANC and post-treatment level of LDH increased in correspondence with the escalation of G-CSF dose. All adverse events normalized on follow-up evaluation. In conclusion, although PBSC harvest for normal donors is acceptable, care must be taken for all donors in terms of their sex and age as well as the G-CSF dose. We recommend less than 8.8 μg/kg/day as the G-CSF dose for PBSC mobilization in normal donors.

Original languageEnglish
Pages (from-to)1065-1071
Number of pages7
JournalBone Marrow Transplantation
Volume24
Issue number10
Publication statusPublished - 1999

Fingerprint

Hematopoietic Stem Cell Mobilization
Blood Component Removal
Granulocyte Colony-Stimulating Factor
Leukapheresis
Bone and Bones
Pain
Nausea
Vomiting
Headache
Incidence
Sleep Initiation and Maintenance Disorders
Anorexia
Neutropenia
Platelet Count
Fatigue
Peripheral Blood Stem Cells
Multivariate Analysis
Pediatrics

Keywords

  • Allogeneic transplantation
  • Apheresis
  • Donor
  • Granulocyte colony-stimulating factor
  • Mobilization
  • Peripheral blood stem cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Murata, M., Harada, M., Kato, S., Takahashi, S., Ogawa, H., Okamoto, S., ... Kodera, Y. (1999). Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors. Bone Marrow Transplantation, 24(10), 1065-1071.

Peripheral blood stem cell mobilization and apheresis : Analysis of adverse events in 94 normal donors. / Murata, M.; Harada, M.; Kato, S.; Takahashi, S.; Ogawa, H.; Okamoto, Shinichiro; Tsuchiya, S.; Sakamaki, H.; Akiyama, Y.; Kodera, Y.

In: Bone Marrow Transplantation, Vol. 24, No. 10, 1999, p. 1065-1071.

Research output: Contribution to journalArticle

Murata, M, Harada, M, Kato, S, Takahashi, S, Ogawa, H, Okamoto, S, Tsuchiya, S, Sakamaki, H, Akiyama, Y & Kodera, Y 1999, 'Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors', Bone Marrow Transplantation, vol. 24, no. 10, pp. 1065-1071.
Murata, M. ; Harada, M. ; Kato, S. ; Takahashi, S. ; Ogawa, H. ; Okamoto, Shinichiro ; Tsuchiya, S. ; Sakamaki, H. ; Akiyama, Y. ; Kodera, Y. / Peripheral blood stem cell mobilization and apheresis : Analysis of adverse events in 94 normal donors. In: Bone Marrow Transplantation. 1999 ; Vol. 24, No. 10. pp. 1065-1071.
@article{d5fd8800bfd9479080db94407ae973fb,
title = "Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors",
abstract = "Adverse events were analyzed in 94 normal donors who underwent PBSC harvest with G-CSF. The median dose of G-CSF was 9.7 μg/kg/day (range, 2.0-16.7), and the duration of administration was 4-6 days. Frequent symptoms were bone pain (71{\%}), general fatigue (33{\%}), headache (28{\%}), insomnia (14{\%}), anorexia (11{\%}), nausea and/or vomiting (11{\%}). One donor (1{\%}) developed grade 3 toxicity bone pain (WHO criteria). WBC counts and ANC increased during G-CSF administration. After leukapheresis, three donors (3{\%}) developed grade 3 toxicity neutropenia. Platelet counts decreased after leukapheresis. Three donors (3{\%}) developed grade 3 thrombocytopenia. The means of both ALP and LDH increased approximately 1.9-fold compared with pretreatment levels. In one pediatric donor (1{\%}), ALP was elevated to the grade 3 toxicity level. From multivariate analysis, the incidence of bone pain increased when GCSF was given at a dose of 8.8 μg/kg/day or more, headaches were frequent in donors younger than 35 years, and the incidence of nausea and/or vomiting was high in female donors. The peak levels of WBC counts and ANC and post-treatment level of LDH increased in correspondence with the escalation of G-CSF dose. All adverse events normalized on follow-up evaluation. In conclusion, although PBSC harvest for normal donors is acceptable, care must be taken for all donors in terms of their sex and age as well as the G-CSF dose. We recommend less than 8.8 μg/kg/day as the G-CSF dose for PBSC mobilization in normal donors.",
keywords = "Allogeneic transplantation, Apheresis, Donor, Granulocyte colony-stimulating factor, Mobilization, Peripheral blood stem cells",
author = "M. Murata and M. Harada and S. Kato and S. Takahashi and H. Ogawa and Shinichiro Okamoto and S. Tsuchiya and H. Sakamaki and Y. Akiyama and Y. Kodera",
year = "1999",
language = "English",
volume = "24",
pages = "1065--1071",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Peripheral blood stem cell mobilization and apheresis

T2 - Analysis of adverse events in 94 normal donors

AU - Murata, M.

AU - Harada, M.

AU - Kato, S.

AU - Takahashi, S.

AU - Ogawa, H.

AU - Okamoto, Shinichiro

AU - Tsuchiya, S.

AU - Sakamaki, H.

AU - Akiyama, Y.

AU - Kodera, Y.

PY - 1999

Y1 - 1999

N2 - Adverse events were analyzed in 94 normal donors who underwent PBSC harvest with G-CSF. The median dose of G-CSF was 9.7 μg/kg/day (range, 2.0-16.7), and the duration of administration was 4-6 days. Frequent symptoms were bone pain (71%), general fatigue (33%), headache (28%), insomnia (14%), anorexia (11%), nausea and/or vomiting (11%). One donor (1%) developed grade 3 toxicity bone pain (WHO criteria). WBC counts and ANC increased during G-CSF administration. After leukapheresis, three donors (3%) developed grade 3 toxicity neutropenia. Platelet counts decreased after leukapheresis. Three donors (3%) developed grade 3 thrombocytopenia. The means of both ALP and LDH increased approximately 1.9-fold compared with pretreatment levels. In one pediatric donor (1%), ALP was elevated to the grade 3 toxicity level. From multivariate analysis, the incidence of bone pain increased when GCSF was given at a dose of 8.8 μg/kg/day or more, headaches were frequent in donors younger than 35 years, and the incidence of nausea and/or vomiting was high in female donors. The peak levels of WBC counts and ANC and post-treatment level of LDH increased in correspondence with the escalation of G-CSF dose. All adverse events normalized on follow-up evaluation. In conclusion, although PBSC harvest for normal donors is acceptable, care must be taken for all donors in terms of their sex and age as well as the G-CSF dose. We recommend less than 8.8 μg/kg/day as the G-CSF dose for PBSC mobilization in normal donors.

AB - Adverse events were analyzed in 94 normal donors who underwent PBSC harvest with G-CSF. The median dose of G-CSF was 9.7 μg/kg/day (range, 2.0-16.7), and the duration of administration was 4-6 days. Frequent symptoms were bone pain (71%), general fatigue (33%), headache (28%), insomnia (14%), anorexia (11%), nausea and/or vomiting (11%). One donor (1%) developed grade 3 toxicity bone pain (WHO criteria). WBC counts and ANC increased during G-CSF administration. After leukapheresis, three donors (3%) developed grade 3 toxicity neutropenia. Platelet counts decreased after leukapheresis. Three donors (3%) developed grade 3 thrombocytopenia. The means of both ALP and LDH increased approximately 1.9-fold compared with pretreatment levels. In one pediatric donor (1%), ALP was elevated to the grade 3 toxicity level. From multivariate analysis, the incidence of bone pain increased when GCSF was given at a dose of 8.8 μg/kg/day or more, headaches were frequent in donors younger than 35 years, and the incidence of nausea and/or vomiting was high in female donors. The peak levels of WBC counts and ANC and post-treatment level of LDH increased in correspondence with the escalation of G-CSF dose. All adverse events normalized on follow-up evaluation. In conclusion, although PBSC harvest for normal donors is acceptable, care must be taken for all donors in terms of their sex and age as well as the G-CSF dose. We recommend less than 8.8 μg/kg/day as the G-CSF dose for PBSC mobilization in normal donors.

KW - Allogeneic transplantation

KW - Apheresis

KW - Donor

KW - Granulocyte colony-stimulating factor

KW - Mobilization

KW - Peripheral blood stem cells

UR - http://www.scopus.com/inward/record.url?scp=0032708430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032708430&partnerID=8YFLogxK

M3 - Article

C2 - 10578156

AN - SCOPUS:0032708430

VL - 24

SP - 1065

EP - 1071

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -